Prelude Capital Management’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Prelude Capital Management’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-251,341	Closed	-$560K	–	1851
2017 Q4	$560K	Buy	251,341 +111,637	+80%	+$278K	0.05%	390
2017 Q3	$405K	Sell	139,704 -54,740	-28%	-$187K	0.04%	435
2017 Q2	$865K	Sell	194,444 -305,854	-61%	-$1.26M	0.08%	238
2017 Q1	$2.33M	Buy	500,298 +276,862	+124%	+$1.61M	0.22%	108
2016 Q4	$1.36M	Buy	223,436 +85,566	+62%	+$447K	0.16%	159
2016 Q3	$760K	Buy	+137,870	New	+$645K	0.08%	247
2016 Q2	–	Sell	-10,000	Closed	-$28K	–	1841
2016 Q1	$28K	Sell	10,000 -18,900	-65%	-$68.4K	﹤0.01%	1070
2015 Q4	$164K	Buy	28,900 +18,500	+178%	+$113K	0.03%	647
2015 Q3	$55K	Sell	10,400 -16,600	-61%	-$128K	0.01%	1037
2015 Q2	$224K	Buy	+27,000	New	+$131K	0.03%	543
2014 Q4	–	Sell	-15,000	Closed	-$42K	–	2284
2014 Q3	$42K	Hold	15,000	–	–	0.01%	1446
2014 Q2	$61K	Sell	15,000 -20,000	-57%	-$85K	0.01%	1293
2014 Q1	$186K	Buy	35,000 +19,790	+130%	+$111K	0.02%	763
2013 Q4	$84K	Hold	15,210	–	–	0.01%	930
2013 Q3	$69K	Hold	15,210	–	–	0.01%	885
2013 Q2	$65K	Buy	+15,210	New	+$76.4K	0.01%	786

Other funds holding SGYP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Prelude Capital Management's SGYP Position: Q1 2018 in Review

Prelude Capital Management sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2018, closing a stake of 251,341 shares — an estimated $560K sold.

Prelude Capital Management first reported a position in SGYP in Q2 2013 and held it in 16 quarters. The position peaked at $2.33M in Q1 2017. 147 funds tracked by Wall St. Rank hold SGYP as of Q1 2018.

Prelude Capital Management reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2018 after selling out during the quarter.
Prelude Capital Management sold 251,341 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2018, an estimated $560K.
Prelude Capital Management first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 16 quarters.
Prelude Capital Management's Synergy Pharmaceuticals, Inc Common Stock position peaked at $2.33M in Q1 2017.
147 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2018.

Based on Prelude Capital Management's 13F filing for Q1 2018, filed 15 May 2018.